Characterizing the Linkage of Systemic Hypoxia and Angiogenesis in High-Grade Glioma to Define the Changes in Tumor Microenvironment for Predicting Prognosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new panel of biomarkers from the tumor microenvironment can predict survival in high-grade gliomas (HGG). This liquid biopsy approach identifies inflammation, hypoxia, and angiogenesis markers for personalized HGG therapy.
Area Of Science
- Neuro-oncology
- Tumor Microenvironment Research
- Biomarker Discovery
Background
- High-grade gliomas (HGG) have poor prognoses with limited survival improvements.
- Current prognostication methods for HGG lack precision.
- The tumor microenvironment (TME) plays a critical role in HGG progression.
Purpose Of The Study
- To identify and validate a non-invasive biomarker panel from the TME for precise prognostication in HGG.
- To assess the linked expression of TME components and their prognostic value.
- To explore the potential of a liquid biopsy approach for HGG survival prediction.
Main Methods
- Analysis of 86 therapy-naive HGG patients and 45 controls.
- Screening of systemic biomarker expression using dot-immune assay (DIA), ELISA, and immunocytochemistry (ICC).
- Evaluation of seven TME markers: IL-6, iNOS, HSP70, VEGF, ET1, MMP14, and ICAM1.
Main Results
- Expression of all seven biomarkers was positively associated with glioma grade.
- Circulating levels of these biomarkers negatively correlated with overall survival (p < 0.0001).
- A combined biomarker panel demonstrated higher sensitivity for survival prediction than individual markers.
Conclusions
- The identified biomarker panel effectively distinguishes HGG grades and predicts differential survival.
- Significant intra-association of biomarkers suggests crosstalk between TME components, potentially driven by hypoxia and inflammation.
- This liquid biopsy approach offers a promising tool for personalized HGG therapy and prognostication.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...